Boothbay Fund Management’s LENZ Therapeutics LENZ Stock Holding History

Boothbay Fund Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-39,746	Closed	-$1.15M	–	1846
2024 Q4	$1.15M	Sell	39,746 -14,633	-27%	-$446K	0.03%	602
2024 Q3	$1.29M	Hold	54,379	–	–	0.03%	677
2024 Q2	$940K	Buy	54,379 +31,778	+141%	+$555K	0.02%	742
2024 Q1	$505K	Buy	+22,601	New	+$470K	0.01%	998
2023 Q1	–	Sell	-4,066	Closed	-$94.5K	–	2558
2022 Q4	$94.5K	Buy	+4,066	New	+$94.2K	﹤0.01%	1801
2022 Q3	–	Sell	-2,006	Closed	-$39K	–	2660
2022 Q2	$39K	Buy	+2,006	New	+$44.7K	﹤0.01%	2101

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Boothbay Fund Management's LENZ Position: Q1 2025 in Review

Boothbay Fund Management sold out of LENZ Therapeutics (LENZ) in Q1 2025, closing a stake of 39,746 shares — an estimated $1.15M sold.

Boothbay Fund Management first reported a position in LENZ in Q2 2022 and held it in 6 quarters. The position peaked at $1.29M in Q3 2024. 105 funds tracked by Wall St. Rank hold LENZ as of Q1 2025.

Boothbay Fund Management reported no remaining LENZ Therapeutics position as of Q1 2025 after selling out during the quarter.
Boothbay Fund Management sold 39,746 LENZ Therapeutics shares in Q1 2025, an estimated $1.15M.
Boothbay Fund Management first reported a position in LENZ Therapeutics in Q2 2022 and held it in 6 quarters.
Boothbay Fund Management's LENZ Therapeutics position peaked at $1.29M in Q3 2024.
105 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.